加拿大成人重组带状疱疹疫苗第二剂完成情况的早期观察:一项回顾性数据库研究
该回顾性数据库研究利用IQVIA LRx纵向处方数据库,评估2018年1月至2019年5月加拿大≥50岁成人接种重组带状疱疹疫苗(RZV)后第二剂完成情况。6个月队列(155,747人)中65.0%在2-6个月内完成第二剂,12个月队列(55,524人)中74.9%在2-12个月内完成,完成率随年龄和地理区域有差异。结论认为第二剂完成率较高但仍不理想。
要点
- 6个月队列中65.0%在2-6个月内完成第二剂RZV。
- 12个月队列中74.9%在2-12个月内完成第二剂RZV。
- 完成率随年龄和地理区域变化,性别、城乡和药房类型无影响。
核心结论
- 加拿大成人RZV第二剂完成率较高但未达最优,需进一步研究影响第二剂时机与完成的因素。
研究设计与样本
- 回顾性数据库研究,数据来自IQVIA LRx纵向处方数据库,追踪匿名患者的零售处方。
- 6个月分析队列155,747人,12个月分析队列55,524人,随访评估第二剂完成情况。
主要发现
- 6个月队列中65.0%在2-6个月内完成第二剂,两剂间截断平均时间为97.8天。
- 12个月队列中74.9%在2-12个月内完成第二剂,两剂间截断平均时间为109.8天。
- 完成率随年龄和地理区域存在差异,性别、城乡和药房类型不影响结果。
关键数值与推荐
- RZV获批用于≥50岁成人预防带状疱疹,两剂间隔2-6个月。
- NACI指出如需灵活性以提高覆盖率,可考虑0、12个月程序。
临床怎么用
- 应关注RZV第二剂完成情况,尤其针对完成率较低的年龄和地理区域人群。
- 可为需要灵活接种程序者考虑NACI推荐的0、12个月方案以提高系列完成率。
局限性
- 原文未报告局限性内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In 2017, the two-dose recombinant zoster vaccine (RZV) was authorized for use in Canada for the prevention of herpes zoster (HZ) in adults ≥ 50 years of age (YOA), which is administered 2-6 months apart. The National Advisory Committee on Immunization (NACI) states that a 0, 12-month schedule may be considered if flexibility in the timing of the second dose is needed to improve coverage. This retrospective database study evaluated the second-dose completion of RZV in Canada from January 2018 to May 2019. METHODS: Data were obtained from the IQVIA LRx Longitudinal Prescription Database which tracks retail prescriptions of anonymized patients. Patients were followed for 6- or 12-months to evaluate the second dose completion aligned with the licensed RZV dosing schedule and NACI's option for greater flexibility. The primary outcomes were time from first to second dose and the proportion of patients who received the second dose. RESULTS: In the 6-month (155,747 patients) and 12-month (55,524 patients) analytic cohorts, 65.0% and 74.9% received the second RZV dose within 2-6 months and 2-12 months after the first dose with a truncated mean time of 97.8 days and 109.8 days between doses, respectively. Variation in completion rates was observed across age and geography, but sex, rurality, and pharmacy type did not impact results. CONCLUSION: Second dose completion of RZV in Canada is high but suboptimal. Further research to understand the factors influencing second dose timing and completion will be an important next step to improve series completion.
引用
- McGirr A, Bourgoin T, Wortzman M, et al. An early look at the second dose completion of the recombinant zoster vaccine in Canadian adults: A retrospective database study. Vaccine. 2021. PMID: 34001346. doi:10.1016/j.vaccine.2021.04.053
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。